Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>GoodRx Holdings, Inc. reported second quarter 2026 results that highlighted ongoing strategic shifts and growth in key areas amid a changing healthcare landscape.</li><li>Total revenue reached $200.4 million with an adjusted EBITDA of $63.7 million, reflecting a margin of 31.8%.</li><li>The company raised its full-year revenue guidance to between $790 million and $805 million and adjusted EBITDA guidance to $240 million–$250 million, driven by strong performance in its Pharma Direct and subscription offerings.</li></ul>

GoodRx Holdings, Inc. reported second quarter 2026 results that highlighted ongoing strategic shifts and growth in key areas amid a changing healthcare landscape.Total revenue reached $200.4 million with an adjusted EBITDA of $63.7 million, reflecting a margin of 31.8%.The company raised its full-year revenue guidance to between $790 million and $805 million and adjusted EBITDA guidance to $240 million–$250 million, driven by strong performance in its Pharma Direct and subscription offerings.

GoodRx’s $28.5 Million Subscription Engine — Recurring Revenue Gains Momentum!

<ul><li>GoodRx reported its financial results for the first quarter of 2026, showing mixed performance across its business segments with growth in some areas offsetting declines in others.</li><li>The company recorded total revenue of $194 million and an adjusted EBITDA of $58.3 million, translating into a 30% margin.</li><li>While prescription transaction revenue declined by 24% year-over-year to $113.7 million, monthly active consumers remained flat sequentially at approximately 5.3 million.</li></ul>

GoodRx reported its financial results for the first quarter of 2026, showing mixed performance across its business segments with growth in some areas offsetting declines in others.The company recorded total revenue of $194 million and an adjusted EBITDA of $58.3 million, translating into a 30% margin.While prescription transaction revenue declined by 24% year-over-year to $113.7 million, monthly active consumers remained flat sequentially at approximately 5.3 million.

GoodRx’s Pharma Direct Surge: Can 82% Growth Offset Rx Marketplace Pressure?

<ul><li>GoodRx's third-quarter 2025 earnings call presented both opportunities and challenges for the company.</li><li>On the positive side, GoodRx showcased a strong quarter with focused execution and significant developments in Manufacturer Solutions.</li><li>The company reported a 54% year-over-year revenue growth in this segment, bolstered by new brand collaborations, particularly with big pharmaceutical players like Novo Nordisk and Amgen.</li></ul>

GoodRx's third-quarter 2025 earnings call presented both opportunities and challenges for the company.On the positive side, GoodRx showcased a strong quarter with focused execution and significant developments in Manufacturer Solutions.The company reported a 54% year-over-year revenue growth in this segment, bolstered by new brand collaborations, particularly with big pharmaceutical players like Novo Nordisk and Amgen.

GoodRx Holdings Inc.: An Insight Into Its Manufacturer Solutions Expansion

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul>
  <li>GoodRx operates a leading digital healthcare platform in the U.S., capitalizing on the opaque and high-cost prescription drug market by offering price transparency and discounts, primarily earning revenue from Pharmacy Benefit Managers (PBMs).</li>
  <li>The company faces a highly competitive and evolving landscape with threats from direct competitors, large new entrants like Amazon, and disruptive models such as Mark Cuban's Cost Plus Drugs, alongside significant reliance on a concentrated number of PBM partners.</li>
  <li>Future growth hinges on diversifying revenue streams beyond prescription transactions into pharma manufacturer solutions, subscription services (GoodRx Gold), and telehealth (GoodRx Care), while navigating regulatory risks and strengthening direct relationships with pharmacies.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  GoodRx operates a leading digital healthcare platform in the U.S., capitalizing on the opaque and high-cost prescription drug market by offering price transparency and discounts, primarily earning revenue from Pharmacy Benefit Managers (PBMs).
  The company faces a highly competitive and evolving landscape with threats from direct competitors, large new entrants like Amazon, and disruptive models such as Mark Cuban's Cost Plus Drugs, alongside significant reliance on a concentrated number of PBM partners.
  Future growth hinges on diversifying revenue streams beyond prescription transactions into pharma manufacturer solutions, subscription services (GoodRx Gold), and telehealth (GoodRx Care), while navigating regulatory risks and strengthening direct relationships with pharmacies.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: GoodRx Holdings Inc (GDRX US) - Oct 2025

<ul><li>GoodRx's recent results for the first quarter of 2025 reflected a mixed performance and strategic repositioning under the new leadership of CEO Wendy Barnes, who marked her first 100 days in the role.</li><li>The company reported total revenue of $203 million, a year-over-year increase of 3%, with prescription transaction revenue and manufacturer solutions growing by 2% and 17%, respectively.</li><li>GoodRx also achieved an adjusted EBITDA of $69.8 million, up 11% from the previous year, indicating a solid profit margin.</li></ul>

GoodRx's recent results for the first quarter of 2025 reflected a mixed performance and strategic repositioning under the new leadership of CEO Wendy Barnes, who marked her first 100 days in the role.The company reported total revenue of $203 million, a year-over-year increase of 3%, with prescription transaction revenue and manufacturer solutions growing by 2% and 17%, respectively.GoodRx also achieved an adjusted EBITDA of $69.8 million, up 11% from the previous year, indicating a solid profit margin.

GoodRx Holdings: Is The Growth in Pharma Manufacturer Solutions Here To Stay?

United States

GoodRx Holdings, Inc. operates a digital healthcare platform. The Company develops tele-medicine platform and a free-to-use website. GoodRx Holdings serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

GoodRx Holdings Inc (GDRX US)

GoodRx’s $28.5 Million Subscription Engine — Recurring Revenue Gains Momentum!

GoodRx Holdings, Inc. reported second quarter 2026 results that highlighted ongoing strategic shifts and growth in key areas amid a changing...

Baptista Research

GoodRx’s Pharma Direct Surge: Can 82% Growth Offset Rx Marketplace Pressure?

GoodRx reported its financial results for the first quarter of 2026, showing mixed performance across its business segments with growth in some...

Baptista Research

GoodRx Holdings Inc.: An Insight Into Its Manufacturer Solutions Expansion

GoodRx's third-quarter 2025 earnings call presented both opportunities and challenges for the company. On the positive side, GoodRx showcased a...

Baptista Research

Primer: GoodRx Holdings Inc (GDRX US) - Oct 2025

GoodRx operates a leading digital healthcare platform in the U.S., capitalizing on the opaque and high-cost prescription drug market by offering...

αSK Primers

GoodRx Holdings: Is The Growth in Pharma Manufacturer Solutions Here To Stay?

GoodRx's recent results for the first quarter of 2025 reflected a mixed performance and strategic repositioning under the new leadership of CEO...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)